American Society of Hematology Annual Meeting & Exposition (ASH) | Conference

Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL
January 25, 2021

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL
January 23, 2021

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL
January 21, 2021

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.